These results suggest that current trials using GLS1 inhibition as a therapeutic approach targeting glutamine metabolism in cancer should take into account other metabolic pathways that can upregulate glutamate production such as the glutaminase II pathway via GTK. The gene discussed is GLS; the disease is cancer.